A director of Espey Manufacturing and Electronics Corp sold 100 shares at $64.49 each, reducing his holdings to 20,550 shares. This insider sale happened after the company reported strong 2026 financial results, including net sales growth to $46.1 million and net income of $11.2 million. However, the stock is considered significantly overvalued, trading 111.9% above its estimated fair value of $30.97. The sale may reflect concerns about the high valuation despite the company's solid financial health and a perfect financial strength rating.
Espey Manufacturing and Electronics Corp insider share sale provides context for the Technology sector's performance on Pluang. For readers following Technology stocks, here is Pluang's market snapshot as of Sep 29, 2026 03:03 WIB: Of 150 priced Technology-sector US stocks tradable on Pluang, 36 rose and 113 fell today. Notable movers include AXTI at USD 73.11 with a 1-day change of -7.39% and Pluang order activity showing 12% Sell / 88% Buy, QCOM at USD 187.20 down 7.27% with 23% Sell / 77% Buy, and BB at USD 8.78 up 6.94% with 17% Sell / 83% Buy.
Conagra Brands is set to report Q1 earnings with analysts forecasting a 1.4% revenue decline to about $2.59 billion due to weak consumer spending and inflation. Earnings per share are expected to drop 20.5% to $0.31, reflecting margin pressures and a...
Morgan Stanley raised the price target for Reinsurance Group of America (RGA) to $295, implying a 16.7% upside from its current price of $252.85. The company reported a 42% increase in adjusted operating income to $746 million in H1, driven by its lo...
H.C. Wainwright raised Mirum Pharmaceuticals' price target from $140 to $195 following positive developments: the Phase 3 AZURE-1 trial for Brelovitug met its main goal for treating Chronic Hepatitis Delta Virus, and the FDA approved Atebrioz™ for Fi...
Kodiak Sciences reported successful Phase 3 trial results for its retinal disease treatments Zenkuda and tabirafusp-ted, showing vision improvements comparable to Regeneron's Eylea. Zenkuda allowed 54% of patients to maintain a six-month dosing inter...
Citigroup has maintained a Neutral rating on Regeneron Pharmaceuticals due to increasing competition in the ophthalmology sector. Kodiak Sciences reported positive Phase 3 trial results for its eye drugs, challenging Regeneron's key product, Eylea, e...
